Lantz Financial LLC Has $229,000 Stock Position in Stryker Corporation $SYK

Lantz Financial LLC lowered its stake in Stryker Corporation (NYSE:SYK) by 6.6% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 579 shares of the medical technology company’s stock after selling 41 shares during the period. Lantz Financial LLC’s holdings in Stryker were worth $229,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of SYK. Capital A Wealth Management LLC acquired a new position in Stryker in the 4th quarter valued at about $26,000. Goodman Advisory Group LLC acquired a new position in shares of Stryker during the 1st quarter worth approximately $32,000. City Holding Co. grew its position in shares of Stryker by 528.6% during the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company’s stock worth $33,000 after purchasing an additional 74 shares in the last quarter. Ransom Advisory Ltd acquired a new position in shares of Stryker during the 1st quarter worth approximately $37,000. Finally, Smallwood Wealth Investment Management LLC acquired a new position in shares of Stryker during the 1st quarter worth approximately $40,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares of the company’s stock, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Viju Menon sold 500 shares of the firm’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by company insiders.

Stryker Price Performance

SYK stock opened at $376.61 on Friday. The company has a fifty day moving average price of $387.52 and a 200-day moving average price of $379.07. The company has a market capitalization of $143.98 billion, a P/E ratio of 49.88, a PEG ratio of 2.71 and a beta of 0.93. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $5.92 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. As a group, equities analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

Analyst Ratings Changes

A number of research analysts have issued reports on SYK shares. BTIG Research restated a “buy” rating on shares of Stryker in a research report on Monday, July 14th. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research report on Thursday. Rothschild & Co Redburn started coverage on shares of Stryker in a research report on Thursday. They set a “neutral” rating and a $420.00 target price on the stock. Redburn Partners set a $420.00 target price on shares of Stryker in a research report on Thursday. Finally, Needham & Company LLC increased their target price on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Fourteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $430.33.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.